AbbVie Inc. (ABBV) reported results in line with expectations in Q2 FY2026 on revenue of $17.0B versus the $16.8B estimate (+10.2% YoY) and EPS of $3.65. The next AbbVie Inc. (ABBV) earnings date is Oct 30, 2026. Below is the full AbbVie Inc. earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
AbbVie Inc. (ABBV) Earnings Analysis — key stats
Next earnings date
Oct 30, 2026
Latest reported quarter
Q2 FY2026
Earnings verdict
In line
EPS beat rate
6 of last 8 (quarters above estimate)
Avg next-day move
±5.9% (over the last 8 reports)
Post-earnings direction
Up 5 / Down 3 (of the last 8 reports)
Implied move (next report)
±11.6% (options-derived · into Oct 30, 2026)
Revenue
$17.0B (vs $16.8B est · +1.1% surprise · +10.2% YoY)
EPS
$3.65 (vs $3.61 est · +1.1% surprise · +284.9% YoY)
Share price
$264.52 (-0.2%)
Market cap
$467.4B
AbbVie Inc. (ABBV) Earnings Analysis — beat / miss history
Quarter
Revenue
EPS
EPS surprise
Next-day move
Verdict
Q3 FY2026
$17.0B vs $16.8B est
$3.65 vs $3.61 est
+1.1%
-4.8%
In line
Q2 FY2026
$15.0B vs $14.7B est
$2.65 vs $2.59 est
+2.3%
+6.9%
Mixed
Q1 FY2026
$16.6B vs $16.4B est
$2.71 vs $2.65 est
+2.3%
-2.9%
Mixed
Q4 FY2025
$15.8B vs $15.6B est
$1.86 vs $1.77 est
+5.1%
-7.1%
Mixed
Q3 FY2025
$15.4B vs $15.0B est
$2.97 vs $2.88 est
+3.1%
+3.1%
Beat
Q2 FY2025
$13.3B vs $12.9B est
$2.46 vs $2.38 est
+3.4%
+6.6%
Beat
Q1 FY2025
$15.1B vs $14.8B est
$2.16 vs $2.98 est
-27.5%
+8.2%
Mixed
Q4 FY2024
$14.5B vs $14.3B est
$3.00 vs $2.92 est
+2.7%
+7.6%
Mixed
What you'll find
Next AbbVie Inc. (ABBV) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment AbbVie Inc. reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in AbbVie Inc. (ABBV)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is AbbVie Inc.'s next earnings date?
AbbVie Inc.'s (ABBV) next scheduled earnings date is Oct 30, 2026. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did AbbVie Inc. (ABBV) beat or miss earnings?
In Q2 FY2026, AbbVie Inc. (ABBV) posted in-line results — revenue of $17.0B versus the $16.8B estimate (+1.1% surprise) and EPS of $3.65 versus $3.61 expected (+1.1% surprise). Magnisto decodes every AbbVie Inc. (ABBV) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
How often does AbbVie Inc. beat earnings estimates?
Over its last 8 reported quarters, AbbVie Inc. (ABBV) beat Wall Street EPS estimates 6 times, most recently a in-line result in Q3 FY2026. Magnisto tracks every AbbVie Inc. (ABBV) quarter's revenue and EPS versus consensus and grades each one Beat, Miss, In-line or Mixed at a unified ±2% threshold.
How much does AbbVie Inc. stock move after earnings?
Over its last 8 quarterly reports, AbbVie Inc. (ABBV) moved an average of ±5.9% the day after earnings — ranging from -7.1% (Q4 FY2025) to +8.2% (Q1 FY2025). The stock rose after 5 of those 8 reports and fell after 3. Heading into its next report on Oct 30, 2026, options-implied volatility is pricing in a move of roughly ±11.6% (derived). Magnisto tracks the realized post-earnings move for every AbbVie Inc. (ABBV) quarter alongside the beat/miss verdict — past moves don't predict the next one.
What is the forecast for AbbVie Inc. (ABBV) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for AbbVie Inc. (ABBV), anchored to the current $264.52 share price, so you can weigh the bull, base and bear cases for AbbVie Inc. side by side.
Is AbbVie Inc. (ABBV) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether AbbVie Inc. fits your own thesis and risk profile. This is research, not investment advice.